Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001242449 | SCV001415539 | uncertain significance | 3-Methylglutaconic aciduria type 3; Optic atrophy 3 | 2022-07-19 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamine, which is neutral and polar, with proline, which is neutral and non-polar, at codon 137 of the OPA3 protein (p.Gln137Pro). This variant is present in population databases (rs372161100, gnomAD 0.006%). This variant has not been reported in the literature in individuals affected with OPA3-related conditions. ClinVar contains an entry for this variant (Variation ID: 967515). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Revvity Omics, |
RCV003130220 | SCV003814270 | uncertain significance | not provided | 2022-06-08 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV003130220 | SCV005408868 | uncertain significance | not provided | 2024-04-01 | criteria provided, single submitter | clinical testing | PM2_moderate |
Natera, |
RCV001835128 | SCV002088918 | uncertain significance | 3-Methylglutaconic aciduria type 3 | 2020-06-12 | no assertion criteria provided | clinical testing |